Regulus Therapeutics Inc.
RGLS
Hisse Senetlerindeki Sıralama
#17278
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Hisse Fiyatı
$8.16
Son senkronizasyon: 2025-06-26
Piyasa Değeri
$234.57M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
-88.86%
Ülke
US
Ticaret Regulus Therapeutics Inc. (RGLS)
Kategori
Healthcare
Regulus Therapeutics Inc. (RGLS) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $73.27 - 2024-11-01
Gün sonu en düşük fiyat: $21.00 - 2010-04-01
Gün sonu en düşük fiyat: $21.00 - 2010-04-01
Regulus Therapeutics Inc. için hisse fiyatı geçmişi: 2010 - 2026
Yıllık Hisse Fiyatı Performansı
| Yıl | Performans |
|---|---|
| 2024 | 113.53% |
| 2023 | 140.97% |
| 2022 | -61.38% |
| 2021 | -67.58% |
| 2020 | -13.91% |
| 2019 | 22.71% |
| 2018 | 12.94% |
| 2017 | 104.37% |
| 2016 | -25.20% |
| 2015 | -38.37% |
| 2014 | 34.13% |
| 2013 | 93.41% |
| 2012 | 67.05% |
| 2011 | 2.83% |
| 2010 | 0.00% |
Benzer şirketler veya rakiplerin hisse fiyatı
| Şirket | Hisse fiyatı | Değişim 1yıl% | Ülke |
|---|---|---|---|
| $525.30 | 23.23% |
US
|
|
| $252.60 | 818.88% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $888.91 | 6.49% |
NL
|
|
| $752.87 | 7.40% |
CH
|
